[The state of the art of imaging in gastroenteropancreatic neuroendocrine tumors]

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 Jan;45(1):51-5. doi: 10.3785/j.issn.1008-9292.2016.01.08.
[Article in Chinese]

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are neoplasms presenting unpredictable and unusual biologic behavior that causes many clinical challenges. NETs can produce a variety of metabolically active substances (hormones and amines) leading to distinct clinical syndromes. This review will discuss the imaging techniques for the diagnosis of GEP-NETs including ultrasonography, CT, MRI and ultrasound endoscope. In this article, Gallium-68 labeled peptide binding to G protein coupled receptor including SSTR, CCKR1 and GLP1R is addressed, and the application of Gallium-68 labeled somatostin analogues and PET-CT for diagnosis of GEP-NETs is evaluated. In conclusion, Gallium-68 labeled peptide and molecular imaging will play important roles in diagnosis, prognosis and therapeutic strategy development of GEP-NETs.

胃肠胰神经内分泌肿瘤(GEP-NET)是具有神经内分泌标志物和产生多肽激素的一类生物学行为各异且难以预测的肿瘤。本文简要介绍CT、MRI、超声和内镜对GEP-NET的诊断价值, 重点介绍针对GEP-NET高表达生长抑素受体、G蛋白偶联受体、胆囊收缩素受体、胰高血糖素相关肽受体等, 放射性核素 68镓与其他放射性核素标记核素分子显像剂的最新进展及分子成像在GEP-NET中的诊断价值、检查前注意事项和临床适应证。 68镓标记生长抑素类似物及正电子发射计算机断层显像(PET-CT)已成为GEP-NET诊断的金标准, 对临床治疗决策起关键作用。G蛋白偶联受体和胰高血糖素相关肽等新的靶向分子探针的不断涌现, 生长抑素受体介导的肿瘤显像在GEP-NET诊疗中将会发挥更大作用。

Publication types

  • Review

MeSH terms

  • Diagnostic Imaging / methods*
  • Endoscopy
  • Gallium Radioisotopes / chemistry
  • Humans
  • Intestinal Neoplasms / diagnosis*
  • Magnetic Resonance Imaging
  • Neuroendocrine Tumors / diagnosis*
  • Pancreatic Neoplasms / diagnosis*
  • Prognosis
  • Receptors, G-Protein-Coupled / chemistry
  • Stomach Neoplasms / diagnosis*
  • Tomography, X-Ray Computed
  • Ultrasonography

Substances

  • Gallium Radioisotopes
  • Receptors, G-Protein-Coupled

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor

Grants and funding

国家自然科学基金(81271604);江苏临床医学专项(BL2012037);南京市科技局课题(YKK14089);CSCO-神经内分泌肿瘤发展基金(Y-N2914-004)